Basic Zydena Information

• INN (International Nonproprietary Name): Udenafil.
• Brand Names Available In United Kingdom: Zydena, Zidena and Udenafilo are the international brand names associated with udenafil, but none are approved for sale in the UK by the MHRA as of July 2025.
• ATC Code: G04BE10 (Genito‑urinary system and sex hormones → Drugs used in erectile dysfunction → Phosphodiesterase type‑5 inhibitors).
• Forms & Dosages: Tablet, commonly 100 mg (blisters of 4, 8 or 10 tablets) and 200 mg (blisters of 4 or 8 tablets) in markets such as Korea, CIS and parts of Asia.
• Manufacturers In United Kingdom: Not specified — originator manufacturer is Dong‑A Pharmaceutical (Seoul, South Korea); no UK manufacturer is listed in public data.
• Registration Status In United Kingdom: Not approved in the UK or EU as of July 2025; registered and marketed in South Korea (approval since 2005), Russia/CIS and the Philippines.
• OTC / Rx Classification: Prescription only (Rx) in all countries where udenafil is registered.

Key Findings From Recent Trials

Major 2022–2025 Studies

Patients and clinicians ask whether recent evidence supports udenafil as a practical option for erectile dysfunction.

Most recent trials between 2022 and 2025 are regional, coming mainly from Korea and CIS publications and comprising small‑to‑midsize randomised and open‑label studies.

There is no large multinational Phase III programme reported in the public data for this period.

Network meta‑analyses including regional trials place udenafil’s efficacy between sildenafil and tadalafil for some endpoints, but confidence intervals are wide.

Real‑world registries from e‑pharmacy datasets in Asia and CIS add pragmatic information on use patterns and dosing adherence.

Keywords naturally found in these reports include udenafil, Zydena and erectile function trials, which appear across trial summaries and patient registries.

Main Outcomes

Trial outcomes consistently report a rapid onset of action with median times around 30–60 minutes, supporting on‑demand dosing.

Participants commonly experienced clinically meaningful improvements in erectile function scores compared with baseline measurements.

Many studies note a duration of effect reported up to roughly 12 hours in a substantial proportion of users, providing a longer functional window than shorter‑acting agents.

Comparative head‑to‑head randomised controlled trials are limited, so direct superiority claims versus sildenafil, tadalafil or vardenafil are not well established in multinational datasets.

Safety Observations

Safety findings align with the PDE5 inhibitor class rather than revealing unique toxicities for udenafil.

Common adverse events reported across studies are headache, flushing, nasal congestion and dyspepsia.

Transient visual disturbances are reported less frequently than with sildenafil in some regional publications, though absolute incidence is low.

Long‑term safety data exceeding one year are sparse outside South Korea, so long‑term pharmacovigilance remains limited.

Clinical Mechanism Of Action

Layman’s Explanation

People wonder how udenafil helps with erections and whether it is different from Viagra or Cialis.

Udenafil helps produce and maintain erections by increasing blood flow to the penis when sexual stimulation occurs.

It amplifies the chemical signals that relax the smooth muscle of penile blood vessels so more blood can enter and stay in the corpora cavernosa.

Scientific Breakdown

Udenafil is a phosphodiesterase type‑5 (PDE5) inhibitor, ATC code G04BE10.

It inhibits PDE5 in cavernosal tissue, preventing breakdown of cyclic GMP (cGMP) and thereby prolonging smooth muscle relaxation and vasodilation during sexual stimulation.

Originator pharmacokinetic data report a median onset of approximately 30–60 minutes and an effect window up to around 12 hours, consistent with on‑demand dosing.

PDE5 Selectivity And Consequences

Udenafil’s PDE5 selectivity profile is broadly similar to other agents in the class, with modest differences in off‑target inhibition of other PDE isoforms reported in pharmacology comparisons.

Those modest differences may contribute to relatively fewer transient visual effects compared with sildenafil in some datasets.

Clinical consequences are class‑wide: similar contraindications and drug interactions apply, most importantly the absolute contraindication with nitrates.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Patients often ask whether zydena can be prescribed through NHS or typical UK clinics.

As of July 2025, udenafil (Zydena/Zidena) is approved and marketed in South Korea and registered in several CIS countries and the Philippines.

There is no approval reported for the United States, Canada or the European Union, and no ANMDMR/EMA registration for the EU as of July 2025.

Therefore, udenafil should be considered unlicensed in the UK unless a specific MHRA licence is later issued.

Notable Off‑Label Trends

In Asia and CIS markets some clinicians and patients experiment with low‑dose daily regimens, but this is not a labelled or widely approved use as of 2025.

Off‑label use has also included situational performance anxiety management, though robust evidence for these applications is limited.

UK prescribers and clinics should avoid sourcing udenafil from unregulated online suppliers and consider licensed UK alternatives such as sildenafil, tadalafil, vardenafil and avanafil where NICE and MHRA guidance applies.

Dosage Strategy

General Dosing

Patients commonly ask what dose to start and how often they can take it.

The labelled initial dose for erectile dysfunction is 100 mg taken orally as needed 30–60 minutes before sexual activity.

The maximum single dose is 200 mg and the maximum frequency is one dose per 24 hours.

Tablets are marketed in 100 mg and 200 mg strengths with typical blister sizes matching local packaging norms.

Condition‑Specific Dosing

Elderly patients generally start at the labelled 100 mg dose and may continue at that dose if tolerated.

Udenafil is not indicated for individuals under 18 years of age.

For renal impairment, cautious use is advised in mild to moderate disease and severe renal failure is not recommended due to lack of data.

In hepatic impairment, mild disease warrants caution while moderate to severe disease is a contraindication in practice because clinical information is insufficient.

Clinicians should titrate conservatively when combining with alpha‑blockers or in patients with borderline blood pressure.

Although regional reports discuss low‑dose daily regimens, these are not part of the authorised label as of 2025.

Safety Protocols

Contraindications

Common prescriber concerns focus on cardiovascular safety and potential drug interactions.

Absolute contraindications include known hypersensitivity to udenafil or any excipients.

Concurrent use with nitrates is absolutely contraindicated because of the risk of severe hypotension.

Severe hepatic or renal impairment and unstable cardiovascular disease (recent myocardial infarction, stroke, unstable angina or severe arrhythmia) are contraindications.

Relative contraindications that require close monitoring are penile anatomical deformities, priapism risk factors (for example sickle cell disease), uncontrolled blood pressure and bleeding disorders.

Adverse Effects

The most commonly reported adverse effects are headache, flushing, nasal congestion and dyspepsia.

Back pain and myalgia have been recorded, and dizziness may occur.

Transient visual disturbances are rare and appear less frequent than with sildenafil in some regional reports.

In overdose situations the main concerns are worsening hypotension and priapism; there is no specific antidote so management is supportive and urgent medical attention is required.

UK prescribers should report serious events via the MHRA Yellow Card system and counsel patients to seek immediate help for erections lasting longer than four hours or any syncope.

Interaction Mapping

Food Interactions

Patients frequently ask whether food delays the effect and how to time dosing.

Originator data do not specify strict diet restrictions beyond general guidance that high‑fat meals can delay absorption for many PDE5 inhibitors and may modestly postpone udenafil onset.

Allow adequate pre‑activity timing of 30–60 minutes to allow for absorption when food intake is substantial.

Drug Combinations To Avoid

Concurrent use with any nitrate medication is an absolute contraindication due to the risk of profound hypotension.

Combining udenafil with alpha‑blockers requires specialist review and monitoring for orthostatic hypotension; patients should be stable on an alpha‑blocker before initiating a PDE5 inhibitor.

Strong CYP3A4 inhibitors, such as certain azole antifungals, some macrolide antibiotics and many protease inhibitors, can increase udenafil exposure and warrant dose adjustment or avoidance.

Co‑administration with other PDE5 inhibitors is not advised.

Antiplatelet or anticoagulant therapies require routine clinical monitoring, though large bleeding signals have not been established in the public data.

Patient Experience Analysis

Survey Data

Many users report they like the balance udenafil provides between onset and duration, giving more spontaneous freedom than sildenafil without committing to tadalafil’s long duration.

Regional patient surveys in Korea and CIS registries show good satisfaction with situational flexibility and a perceived window of effect up to around 12 hours.

An illustrative example: a 52‑year‑old patient described improved confidence on weekend evenings after taking a 100 mg dose 45 minutes before activity, matching the typical onset window reported in trials.

Forum Trends

Online reviews and forums highlight positive efficacy but recurring concerns about sourcing and variable labelling when ordering internationally.

Common consumer advice threads recommend starting at 100 mg, avoiding excessive alcohol with dosing, and consulting a registered prescriber before purchase.

UK users seeking udenafil online face regulatory risk because unlicensed imports may lack UK quality assurance and pharmacovigilance.

Distribution & Pricing Landscape

Licensed Markets & Manufacturers

Udenafil distribution is concentrated in South Korea where Dong‑A Pharmaceutical is the originator manufacturer and in licensed partners across CIS markets.

Brand packaging appears as Zydena in Korea, Zidena across CIS countries and Udenafilo on some online listings with Spanish or Portuguese labelling.

Typical tablet sizes are 100 mg and 200 mg sold in 4–10 tablet blister packs depending on market.

Online And Parallel Trade Risks

Pricing tends to undercut Western brands in markets where it is licensed, but udenafil is prescription‑only where registered.

In the UK market udenafil is unlicensed and supply frequently comes from international e‑pharmacies or parallel imports, which introduces regulatory and quality risks such as relabelling and counterfeit products.

Storage guidance specifies below 25°C, protection from moisture and light — important to verify for cross‑border shipments.

In our online pharmacy, zydena is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

Comparison Table

Patients often want to know whether udenafil is better than Viagra, Cialis or newer options such as Spedra.

All PDE5 inhibitors are effective for erectile dysfunction, but they differ in onset and duration.

Udenafil’s labelled onset of 30–60 minutes and reported duration up to about 12 hours places its functional window between sildenafil and tadalafil in many practical terms.

Pros And Cons

• Pros: Perceived longer functional window than sildenafil, flexible on‑demand dosing, positive patient satisfaction reports in regional surveys.
• Cons: Not licensed in the UK/EU/US as of July 2025, limited multinational long‑term data, sourcing and pharmacovigilance concerns with imports.

Regulatory Status

Global Approvals

Originator Zydena was approved in South Korea in 2005 and is marketed by Dong‑A Pharmaceutical.

Registrations exist across Russia/CIS and in the Philippines under brand names such as Zydena and Zidena.

No approvals in the United States, Canada or the European Union have been reported as of July 2025 in the public data.

UK/EU Position And Implications

Because udenafil lacks MHRA or EMA approval, it is an unlicensed medicine in the UK and does not benefit from the same pharmacovigilance infrastructure as licensed ED medicines.

UK clinicians should avoid routine prescribing of unlicensed udenafil and follow MHRA guidance for any exceptional named‑patient use, which includes documenting a clinical rationale, obtaining informed consent and ensuring reputable sourcing with batch verification where possible.

Consolidated FAQ

Common Questions

Is Zydena available in the UK?

No, there is no MHRA or EMA approval as of July 2025; it should be treated as unlicensed in the UK.

What is the starting dose?

The labelled starting dose is 100 mg taken 30–60 minutes before sexual activity, with a maximum single dose of 200 mg and no more than one dose per 24 hours.

Can I take it with nitrates?

No — concomitant use with nitrates is absolutely contraindicated due to severe hypotension risk.

Is it safe for elderly or those with renal impairment?

Elderly patients may start at 100 mg as tolerated; mild to moderate renal impairment requires caution and severe renal or moderate to severe hepatic impairment should avoid udenafil.

Where is it manufactured?

The originator manufacturer is Dong‑A Pharmaceutical in Seoul, South Korea.

What if I buy online?

Sourcing from unverified e‑pharmacies risks counterfeit product, improper storage and lack of safety reporting; UK patients should consult an NHS‑registered prescriber or pharmacist before use.

UK‑Specific Answers

UK prescribers should favour licensed PDE5 inhibitors such as sildenafil, tadalafil, vardenafil or avanafil for routine care because those medicines are available through regulated supply chains and established guidance.

Visual Guide

Tablet Forms & Packaging

Marketed tablets commonly come in 100 mg and 200 mg strengths and carry brand names such as Zydena, Zidena or Udenafilo on packaging.

Korean packs typically display Korean text and blister sizes of 4, 8 or 10 tablets while CIS packs may use alternate spellings or local languages.

Legitimate product from Dong‑A will show manufacturer details, batch and expiry identifiers on the pack.

Identifying Legitimate Product

Red flags suggesting counterfeit or unregulated imports include misspellings, missing batch or expiry information, different tablet imprints, poor blister quality and unusually low prices.

Storage labelling should state storage below 25°C and protection from moisture and light.

For named‑patient imports, pharmacists should request certificates of analysis and batch documentation before dispensing.

Storage & Transport

Recommended Conditions

Store in the original packaging, protect from moisture and direct sunlight and keep below 25°C (77°F).

Practical Steps For Pharmacies

Pharmacies importing for named‑patient use should document the supply chain, verify batch numbers, inspect packaging on receipt and keep temperature logs if holding stock.

Patients buying abroad should be advised to retain original blister packs and to consult a UK clinician if they have any concerns about authenticity or storage.

Guidelines For Proper Use

Prescriber Checklist

Confirm the diagnosis of erectile dysfunction and assess cardiovascular fitness before prescribing any PDE5 inhibitor.

Review all medications, particularly nitrates, alpha‑blockers and potent CYP3A4 inhibitors.

Check liver and renal function where clinically indicated and discuss the unlicensed status in the UK if considering imported supply, documenting informed consent.

Start at 100 mg or lower if there are clinical concerns and advise the maximum 200 mg in 24 hours.

Record batch details if prescribing imported supply on a named‑patient basis.

Patient Counselling Points

Take the tablet 30–60 minutes before sexual activity and avoid combining with nitrates or excessive alcohol.

Expect common side effects such as headache, flushing and nasal congestion, and seek urgent care for erections lasting longer than four hours.

Report serious adverse events to a GP or via the MHRA Yellow Card scheme.

If the product is imported, verify authenticity with a pharmacist prior to first use.

Delivery Across United Kingdom

Final Practical Notes For UK Patients

When patients ask whether zydena is a straightforward substitute for licensed UK medicines, the answer depends on licensing, supply assurance and individual clinical factors.

For routine treatment, licensed UK options such as sildenafil, tadalafil, vardenafil and avanafil remain the regulated first choice because they are supported by MHRA and NICE guidance.

If a clinician considers udenafil on a named‑patient basis, document the clinical justification, ensure informed consent and verify batch documentation from a reputable supplier before issuing or dispensing.

Keep a copy of product packaging and batch numbers and counsel the patient on expected onset, duration and when to seek urgent care.

For further advice about choice between PDE5 inhibitors, consult a registered prescriber or pharmacist to match onset, duration and interaction risk to the patient's needs.